{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:10:50Z","timestamp":1794964250373,"version":"4.9.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI109711"],"award-info":[{"award-number":["U19AI109711"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-59168-5","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:43:55Z","timestamp":1745426635000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Remdesivir, mAb114, REGN-EB3, and ZMapp partially rescue nonhuman primates infected with a low passage Kikwit variant of Ebola virus"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4147-2077","authenticated-orcid":false,"given":"Abhishek N.","family":"Prasad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3389-0137","authenticated-orcid":false,"given":"Courtney","family":"Woolsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoriya","family":"Borisevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7319-6935","authenticated-orcid":false,"given":"Krystle N.","family":"Agans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Deer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan B.","family":"Geisbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mack B.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Dobias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla A.","family":"Fenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7718-1522","authenticated-orcid":false,"given":"Robert W.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-1877","authenticated-orcid":false,"given":"Thomas W.","family":"Geisbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"59168_CR1","unstructured":"Feldmann, H., Sanchez, A. & Geisbert, T. W. In Fields Virology (eds D. M. Knipe & P. M. Howley) 923\u2013956 (Lippincott Williams & Wilkins, 2013)."},{"key":"59168_CR2","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1056\/NEJMra1901594","volume":"382","author":"H Feldmann","year":"2020","unstructured":"Feldmann, H., Sprecher, A. & Geisbert, T. W. Ebola. New Engl. J. Med. 382, 1832\u20131842 (2020).","journal-title":"New Engl. J. Med."},{"key":"59168_CR3","unstructured":"World Health Organization. Ebola: West Africa, March 2014-2016. https:\/\/www.who.int\/emergencies\/situations\/ebola-outbreak-2014-2016-West-Africa (2023)."},{"key":"59168_CR4","unstructured":"World Health Organization. Ebola: North Kivu\/Ituri, Democratic Republic of the Congo, August 2018\u2014June 2020. https:\/\/www.who.int\/emergencies\/situations\/Ebola-2019-drc (2024)."},{"key":"59168_CR5","doi-asserted-by":"publisher","first-page":"S446","DOI":"10.1093\/infdis\/jiad362","volume":"228","author":"LC Dupuy","year":"2023","unstructured":"Dupuy, L. C. et al. Filoviruses: scientific gaps and prototype pathogen recommendation. J. Infect. Dis. 228, S446\u2013S459 (2023).","journal-title":"J. Infect. Dis."},{"key":"59168_CR6","doi-asserted-by":"crossref","unstructured":"Emanuel, J., Marzi, A. & Feldmann, H. In Advances in Virus Research (eds Kielian M. Mettenleiter. T. C., & Roossinck. M. J.) 189\u2013221 (Academic Press, 2018).","DOI":"10.1016\/bs.aivir.2017.12.002"},{"key":"59168_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nrd.2017.251","volume":"17","author":"RW Cross","year":"2018","unstructured":"Cross, R. W., Mire, C. E., Feldmann, H. & Geisbert, T. W. Post-exposure treatments for Ebola and Marburg virus infections. Nat. Rev. Drug Discov. 17, 413\u2013434 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"59168_CR8","doi-asserted-by":"publisher","first-page":"e1010078","DOI":"10.1371\/journal.ppat.1010078","volume":"17","author":"C Woolsey","year":"2021","unstructured":"Woolsey, C. & Geisbert, T. W. Current state of Ebola virus vaccines: a snapshot. PLoS Pathog. 17, e1010078 (2021).","journal-title":"PLoS Pathog"},{"key":"59168_CR9","doi-asserted-by":"crossref","unstructured":"Liu, C. H., Hu, Y. T., Wong, S. H. & Lin, L. T. Therapeutic strategies against ebola virus infection. Viruses 14, 579 (2022).","DOI":"10.3390\/v14030579"},{"key":"59168_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40265-020-01452-3","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham, A. REGN-EB3: First approval. Drugs 81, 175\u2013178 (2021).","journal-title":"Drugs"},{"key":"59168_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1083429","volume":"14","author":"E Taki","year":"2023","unstructured":"Taki, E. et al. Ebanga: The most recent FDA-approved drug for treating Ebola. Front. Pharmacol. 14, 1083429 (2023).","journal-title":"Front. Pharmacol."},{"key":"59168_CR12","doi-asserted-by":"crossref","unstructured":"Mire, C. E. et al. Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Sci. Transl. Med. 9, eaai8711 (2017).","DOI":"10.1126\/scitranslmed.aai8711"},{"key":"59168_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.chom.2018.12.005","volume":"25","author":"ZA Bornholdt","year":"2019","unstructured":"Bornholdt, Z. A. et al. A Two-antibody pan-ebolavirus cocktail confers broad therapeutic protection in ferrets and nonhuman primates. Cell Host Microbe. 25, 49\u201358 e45 (2019).","journal-title":"Cell Host Microbe."},{"key":"59168_CR14","doi-asserted-by":"crossref","unstructured":"Porter, D. P. et al. Remdesivir (GS-5734) is efficacious in cynomolgus macaques infected with marburg virus. J. Infect. Dis. 222, 1894-1901 (2020).","DOI":"10.1093\/infdis\/jiaa290"},{"key":"59168_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22132-0","volume":"12","author":"RW Cross","year":"2021","unstructured":"Cross, R. W. et al. Combination therapy protects macaques against advanced Marburg virus disease. Nat. Commun. 12, 1891 (2021).","journal-title":"Nat. Commun."},{"key":"59168_CR16","doi-asserted-by":"crossref","unstructured":"Cross, R. W. et al. Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease. JCI Insight 7, e159090 (2022).","DOI":"10.1172\/jci.insight.159090"},{"key":"59168_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08040-w","volume":"10","author":"JM Brannan","year":"2019","unstructured":"Brannan, J. M. et al. Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates. Nat. Commun. 10, 105 (2019).","journal-title":"Nat. Commun."},{"key":"59168_CR18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3390\/pathogens11060655","volume":"11","author":"E Kuang","year":"2022","unstructured":"Kuang, E. et al. Reversion of Ebolavirus disease from a single intramuscular injection of a pan-ebolavirus immunotherapeutic. Pathogens 11, 655 (2022).","journal-title":"Pathogens"},{"key":"59168_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature13777","volume":"514","author":"X Qiu","year":"2014","unstructured":"Qiu, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47\u201353 (2014).","journal-title":"Nature"},{"key":"59168_CR20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature17180","volume":"531","author":"TK Warren","year":"2016","unstructured":"Warren, T. K. et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531, 381\u2013385 (2016).","journal-title":"Nature"},{"key":"59168_CR21","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.aad5224","volume":"351","author":"D Corti","year":"2016","unstructured":"Corti, D. et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351, 1339\u20131342 (2016).","journal-title":"Science"},{"key":"59168_CR22","doi-asserted-by":"publisher","first-page":"S612","DOI":"10.1093\/infdis\/jiy285","volume":"218","author":"KE Pascal","year":"2018","unstructured":"Pascal, K. E. et al. Development of clinical-stage human monoclonal antibodies that treat advanced Ebola virus disease in nonhuman primates. J. Infect. Dis. 218, S612\u2013S626 (2018).","journal-title":"J. Infect. Dis."},{"key":"59168_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98971-0","volume":"11","author":"TK Warren","year":"2021","unstructured":"Warren, T. K. et al. Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus. Sci. Rep. 11, 19458 (2021).","journal-title":"Sci. Rep."},{"key":"59168_CR24","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","volume":"389","author":"AM Henao-Restrepo","year":"2017","unstructured":"Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet 389, 505\u2013518 (2017).","journal-title":"Lancet"},{"key":"59168_CR25","unstructured":"U.S. Food and Drug Administration. First FDA-approved Vaccine For The Prevention Of Ebola Virus Disease, Marking A Critical Milestone In Public Health Preparedness And Response. https:\/\/www.fda.gov\/news-events\/press-announcements\/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health (2019)."},{"key":"59168_CR26","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","volume":"375","author":"Prevail II Writing Group.","year":"2016","unstructured":"Prevail II Writing Group. A randomized, controlled trial of ZMapp for Ebola virus infection. N. Engl. J. Med. 375, 1448\u20131456 (2016).","journal-title":"N. Engl. J. Med."},{"key":"59168_CR27","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","volume":"381","author":"S Mulangu","year":"2019","unstructured":"Mulangu, S. et al. A randomized, controlled trial of Ebola virus disease therapeutics. N. Engl. J. Med. 381, 2293\u20132303 (2019).","journal-title":"N. Engl. J. Med."},{"key":"59168_CR28","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1016\/j.cell.2021.09.035","volume":"184","author":"P Gilchuk","year":"2021","unstructured":"Gilchuk, P. et al. Pan-ebolavirus protective therapy by two multifunctional human antibodies. Cell 184, 5593\u20135607 e5518 (2021).","journal-title":"Cell"},{"key":"59168_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17446-4","volume":"11","author":"RW Cross","year":"2020","unstructured":"Cross, R. W. et al. Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment. Nat. Commun, 11, 3736 (2020).","journal-title":"Nat. Commun,"},{"key":"59168_CR30","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3390\/pathogens11111376","volume":"11","author":"SS Tazerji","year":"2022","unstructured":"Tazerji, S. S., Nardini, R., Safdar, M., Shehata, A. A. & Duarte, P. M. An overview of anthropogenic actions as drivers for emerging and re-emerging zoonotic diseases. Pathogens 11, 1376 (2022).","journal-title":"Pathogens"},{"key":"59168_CR31","unstructured":"Federal Select Agent Program. Select Agents and Toxins List. https:\/\/www.selectagents.gov\/sat\/list.htm (2024)."},{"key":"59168_CR32","unstructured":"National Institute of Allergy and Infectious Diseases. NIAID Emerging Infectious Diseases\/Pathogens. https:\/\/www.niaid.nih.gov\/research\/niaid-biodefense-pathogens (2024)."},{"key":"59168_CR33","doi-asserted-by":"publisher","first-page":"S474","DOI":"10.1093\/infdis\/jiad354","volume":"228","author":"A Sprecher","year":"2023","unstructured":"Sprecher, A. et al. Perspectives on advancing countermeasures for filovirus disease: report from a multisector meeting. J. Infect. Dis. 228, S474\u2013S478 (2023).","journal-title":"J. Infect. Dis."},{"key":"59168_CR34","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1056\/NEJMp1902682","volume":"380","author":"V-K Nguyen","year":"2019","unstructured":"Nguyen, V.-K. An epidemic of suspicion\u2014Ebola and violence in the DRC. N. Engl. J. Med. 380, 1298\u20131299 (2019).","journal-title":"N. Engl. J. Med."},{"key":"59168_CR35","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1177\/2168479016641717","volume":"50","author":"T Allio","year":"2016","unstructured":"Allio, T. Product development under FDA\u2019s animal rule: understanding FDA\u2019s expectations and potential implications for traditional development programs. Ther. Innov. Regul. Sci. 50, 660\u2013670 (2016).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"59168_CR36","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1093\/infdis\/jiv284","volume":"212","author":"TW Geisbert","year":"2015","unstructured":"Geisbert, T. W., Strong, J. E. & Feldmann, H. Considerations in the use of nonhuman primate models of Ebola virus and Marburg virus infection. J. Infect. Dis. 212, S91\u2013S97 (2015).","journal-title":"J. Infect. Dis."},{"key":"59168_CR37","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/0042-6822(83)90258-1","volume":"128","author":"F Sobrino","year":"1983","unstructured":"Sobrino, F., Davila, M., Ortin, J. & Domingo, E. Multiple genetic variants arise in the course of replication of foot-and-mouth disease virus in cell culture. Virology 128, 310\u2013318 (1983).","journal-title":"Virology"},{"key":"59168_CR38","doi-asserted-by":"publisher","first-page":"S295","DOI":"10.1093\/infdis\/jiv216","volume":"212","author":"KJ Alfson","year":"2015","unstructured":"Alfson, K. J. et al. Genetic changes at the glycoprotein editing site associated with serial passage of Sudan virus. J. Infect. Dis. 212, S295\u2013S304 (2015).","journal-title":"J. Infect. Dis."},{"key":"59168_CR39","doi-asserted-by":"publisher","first-page":"S941","DOI":"10.1093\/infdis\/jir321","volume":"204","author":"VA Volchkova","year":"2011","unstructured":"Volchkova, V. A., Dolnik, O., Martinez, M. J., Reynard, O. & Volchkov, V. E. Genomic RNA editing and its impact on Ebola virus adaptation during serial passages in cell culture and infection of guinea pigs. J. Infect. Dis. 204, S941\u2013S946 (2011).","journal-title":"J. Infect. Dis."},{"key":"59168_CR40","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1073\/pnas.93.8.3602","volume":"93","author":"A Sanchez","year":"1996","unstructured":"Sanchez, A., Trappier, S. G., Mahy, B. W., Peters, C. J. & Nichol, S. T. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl Acad. Sci. USA 93, 3602\u20133607 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"59168_CR41","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1128\/JVI.02190-10","volume":"85","author":"M Mehedi","year":"2011","unstructured":"Mehedi, M. et al. A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J. Virol. 85, 5406\u20135414 (2011).","journal-title":"J. Virol."},{"key":"59168_CR42","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3390\/v11110999","volume":"11","author":"W Zhu","year":"2019","unstructured":"Zhu, W., Banadyga, L., Emeterio, K., Wong, G. & Qiu, X. The roles of Ebola virus soluble glycoprotein in replication, pathogenesis, and countermeasure development. Viruses 11, 999 (2019).","journal-title":"Viruses"},{"key":"59168_CR43","doi-asserted-by":"publisher","first-page":"6739","DOI":"10.3390\/v7122969","volume":"7","author":"JC Trefry","year":"2015","unstructured":"Trefry, J. C. et al. Ebola Virus infections in nonhuman primates are temporally influenced by glycoprotein poly-U editing site populations in the exposure material. Viruses 7, 6739\u20136754 (2015).","journal-title":"Viruses"},{"key":"59168_CR44","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3390\/v10110642","volume":"10","author":"K Alfson","year":"2018","unstructured":"Alfson, K. et al. Intramuscular exposure of macaca fascicularis to low doses of low passage- or cell culture-adapted Sudan virus or Ebola virus. Viruses 10, 642 (2018).","journal-title":"Viruses"},{"key":"59168_CR45","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk6176","volume":"383","author":"RW Cross","year":"2024","unstructured":"Cross, R. W. et al. Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus. Science 383, eadk6176 (2024).","journal-title":"Science"},{"key":"59168_CR46","doi-asserted-by":"crossref","unstructured":"Cross, R. W. et al. Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates. Nat. Med. 31, 1303\u20131311 (2025).","DOI":"10.1038\/s41591-025-03496-y"},{"key":"59168_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adw0659","volume":"11","author":"C Woolsey","year":"2025","unstructured":"Woolsey, C. et al. The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infection. Sci. Adv. 11, eadw0659 (2025).","journal-title":"Sci. Adv."},{"key":"59168_CR48","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/nm.4396","volume":"23","author":"CE Mire","year":"2017","unstructured":"Mire, C. E. et al. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat. Med. 23, 1146\u20131149 (2017).","journal-title":"Nat. Med."},{"key":"59168_CR49","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1172\/JCI131958","volume":"130","author":"RW Cross","year":"2020","unstructured":"Cross, R. W. et al. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death. J. Clin. Invest. 130, 539\u2013551 (2020).","journal-title":"J. Clin. Invest."},{"key":"59168_CR50","doi-asserted-by":"publisher","first-page":"e3001687","DOI":"10.1371\/journal.pbio.3001687","volume":"20","author":"DE Griffin","year":"2022","unstructured":"Griffin, D. E. Why does viral RNA sometimes persist after recovery from acute infections? PLoS Biol. 20, e3001687 (2022).","journal-title":"PLoS Biol."},{"key":"59168_CR51","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1093\/cid\/ciw601","volume":"63","author":"B Diallo","year":"2016","unstructured":"Diallo, B. et al. Resurgence of Ebola virus disease in Guinea linked to a survivor with virus persistence in seminal fluid for more than 500\u2009days. Clin. Infect. Dis. 63, 1353\u20131356 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"59168_CR52","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41586-021-03901-9","volume":"597","author":"AK Keita","year":"2021","unstructured":"Keita, A. K. et al. Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks. Nature 597, 539\u2013543 (2021).","journal-title":"Nature"},{"key":"59168_CR53","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1056\/NEJMoa2024670","volume":"384","author":"P Mbala-Kingebeni","year":"2021","unstructured":"Mbala-Kingebeni, P. et al. Ebola virus transmission initiated by relapse of systemic Ebola virus disease. N. Engl. J. Med. 384, 1240\u20131247 (2021).","journal-title":"N. Engl. J. Med."},{"key":"59168_CR54","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1126\/science.aad6117","volume":"351","author":"J Misasi","year":"2016","unstructured":"Misasi, J. et al. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science. 351, 1343\u20131346 (2016).","journal-title":"Science."},{"key":"59168_CR55","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/19420862.2015.1127492","volume":"8","author":"DK Pettit","year":"2016","unstructured":"Pettit, D. K. et al. CHO cell production and sequence improvement in the 13C6FR1 anti-Ebola antibody. Mabs. 8, 347\u2013357 (2016).","journal-title":"Mabs."},{"key":"59168_CR56","doi-asserted-by":"crossref","unstructured":"Mire, C. E. et al. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature 520, 688\u2013691 (2015).","DOI":"10.1038\/nature14428"},{"key":"59168_CR57","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nature14442","volume":"521","author":"EP Thi","year":"2015","unstructured":"Thi, E. P. et al. Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature. 521, 362\u2013365 (2015).","journal-title":"Nature."},{"key":"59168_CR58","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics. 30, 2114\u20132120 (2014).","journal-title":"Bioinformatics."},{"key":"59168_CR59","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1101\/gr.089532.108","volume":"19","author":"JT Simpson","year":"2009","unstructured":"Simpson, J. T. et al. ABySS: A parallel assembler for short read sequence data. Genome Res. 19, 1117\u20131123 (2009).","journal-title":"Genome Res."},{"key":"59168_CR60","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics."},{"key":"59168_CR61","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson, J. T. et al. Integrative genomics viewer. Nat Biotechnol. 29, 24\u201326 (2011).","journal-title":"Nat Biotechnol."},{"key":"59168_CR62","doi-asserted-by":"publisher","first-page":"11189","DOI":"10.1093\/nar\/gks918","volume":"40","author":"A Wilm","year":"2012","unstructured":"Wilm, A. et al. LoFreq: A sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res. 40, 11189\u201311201 (2012).","journal-title":"Nucleic Acids Res."},{"key":"59168_CR63","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/ (2020)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59168-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59168-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59168-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:02:40Z","timestamp":1745431360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59168-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["59168"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-59168-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3824"}}